Home » Archive by Tags

Articles tagged with: biotech

Outside San Diego, Illumina Looks to Wisconsin for Key R&D

May 8, 2014 – 6:37 am | Edit Post
Outside San Diego, Illumina Looks to Wisconsin for Key R&D

When an acquisition occurs, the worst-case scenario for the community of the purchased company usually occurs when the buyer gobbles up the pieces it wants and shutters the local operations. But this…

[[Click headline to continue reading.]]

San Diego’s Synthorx Adds To Genetic Alphabet, Aims for Bio-Products

May 7, 2014 – 11:38 am | Edit Post
San Diego’s Synthorx Adds To Genetic Alphabet, Aims for Bio-Products

[Corrected 5/7/14, 2 pm See below.] A group of scientists in San Diego who found a way to insert synthesized nucleotides into DNA—and who succeeded in coaxing the synthetic DNA to replicate in…

[[Click headline to continue reading.]]

San Diego Life Sciences Roundup: Otonomy, Verdezyne, and IPOs

May 2, 2014 – 6:52 am | Edit Post
San Diego Life Sciences Roundup: Otonomy, Verdezyne, and IPOs

It was another busy week for San Diego’s life sciences sector. Here’s my roundup. —The federal Jumpstart Our Business Startups (JOBS) Act that was enacted two years ago has made it easier for…

[[Click headline to continue reading.]]

Wireless Health Summit: Barriers to Adoption and Tools for Change

May 1, 2014 – 2:31 pm | Edit Post
Wireless Health Summit: Barriers to Adoption and Tools for Change

As a co-founder and CEO of the San Diego-based Wireless-Life Sciences Alliance, Rob McCray has spent the past decade or longer shepherding the convergence of innovative wireless technologies and…

[[Click headline to continue reading.]]

Otonomy Raises $49M to Advance 3 Drugs for Treating Ear Diseases

April 30, 2014 – 4:30 am | Edit Post
Otonomy Raises $49M to Advance 3 Drugs for Treating Ear Diseases

Otonomy, the San Diego biopharmaceutical startup developing new treatments for diseases and disorders of the ear, has refined its strategy, raised capital, and advanced three drug candidates in the…

[[Click headline to continue reading.]]

VCs Invest $243M in San Diego Startups in Q1, Tech Drought Continues

April 18, 2014 – 12:40 am | Edit Post
VCs Invest $243M in San Diego Startups in Q1, Tech Drought Continues

[Corrected 4/18/14, 7:40 am See below.] Venture capital firms invested $243 million in 23 deals in the San Diego area during the first quarter that ended in March, according to data from the…

[[Click headline to continue reading.]]

Scripps Unveils New Drug Development Arm, Signs J&J as First Partner

April 15, 2014 – 3:30 am | Edit Post
Scripps Unveils New Drug Development Arm, Signs J&J as First Partner

Venture capital firms have long nurtured biotechnology startups that make use of discoveries from non-profit research centers—but the roster of such VC firms has been shrinking. To fill the gap…

[[Click headline to continue reading.]]

Announcing Napa Summit 2014: Get An Invite to Xconomy’s Elite Confab

April 8, 2014 – 7:00 am | Edit Post
Announcing Napa Summit 2014: Get An Invite to Xconomy’s Elite Confab

For the past two years, Xconomy has held an invitation-only event in the heart of California wine country with a general focus on the economy, emerging technology, competitiveness, and jobs—and…

[[Click headline to continue reading.]]

San Diego’s Lumena Files for IPO to Fund Liver Drug Trials

April 3, 2014 – 9:01 pm | Edit Post
San Diego’s Lumena Files for IPO to Fund Liver Drug Trials

Lumena Pharmaceuticals has filed for a $75 million IPO, just a few weeks after the San Diego biopharmaceutical company raised $45 million in venture funding. Lumena was founded in 2011 to develop…

[[Click headline to continue reading.]]

San Diego Life Sciences Roundup: Zogenix, Arena, Sorrento, and More

March 31, 2014 – 9:43 am | Edit Post
San Diego Life Sciences Roundup: Zogenix, Arena, Sorrento, and More

San Diego’s Zogenix ran up against new political opposition to its opioid pain-killer, Zohydro. I have a rundown on the latest chapter in the ongoing Zohydro saga, along with the rest of the local…

[[Click headline to continue reading.]]